Entheon Biomedical (TSE:ENBI)
:ENBI
Top Page
Entheon Biomedical
(ENBI)
Select Model
Select Model
Rating:47Neutral
Price Target:
C$0.10
▼(-1.00% Downside)
Action:ReiteratedDate:03/30/26
The score is held down primarily by weak financial performance (zero recent revenue, ongoing losses, and continued cash burn), only partially offset by the lack of debt. Technicals are relatively neutral with slight stabilization, while valuation is constrained by negative earnings and no dividend support.
Positive Factors
Debt-free balance sheet
A debt-free capital structure materially lowers solvency and interest-cost risk, preserving flexibility to fund R&D or survive protracted development timelines without immediate interest payments. This structural advantage reduces bankruptcy risk and lengthens runway versus leveraged peers.
Negative Factors
Zero recent revenue
Absence of product revenue removes internal financing and market validation, forcing reliance on external funding. Over months this increases dilution risk, limits reinvestment in trials, and makes long-term commercialization and scale-up uncertain without fresh capital or partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A debt-free capital structure materially lowers solvency and interest-cost risk, preserving flexibility to fund R&D or survive protracted development timelines without immediate interest payments. This structural advantage reduces bankruptcy risk and lengthens runway versus leveraged peers.
Read all positive factors
Entheon Biomedical (ENBI) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$1.39M
Dividend YieldN/A
Average Volume (3M)7.96K
Price to Earnings (P/E)―
Beta (1Y)4.07
Revenue GrowthN/A
EPS Growth34.22%
CountryCA
Employees1
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding13,858,926
10 Day Avg. Volume17,012
30 Day Avg. Volume7,955
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.72
Price to Sales (P/S)0.00
P/FCF Ratio-3.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Entheon Biomedical Business Overview & Revenue Model
Company Description
Entheon Biomedical Corp. operates as a biotechnology research and drug development company. It engages in developing and commercializing various N,N-dimethyltryptamine based psychedelic therapeutic products for treating addiction and substance use...
How the Company Makes Money
null...
Entheon Biomedical Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | Nov 2025 | Feb 2025 | Feb 2024 | Feb 2023 | Feb 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 250.32K | 189.68K | 21.67K |
| Gross Profit | 0.00 | 0.00 | 250.32K | 189.68K | 9.13K |
| EBITDA | -334.22K | -318.00K | 13.99K | -3.60M | -8.21M |
| Net Income | -324.01K | -318.00K | -300.00K | -8.52M | -8.89M |
Balance Sheet | |||||
| Total Assets | 353.78K | 185.14K | 401.08K | 769.22K | 9.98M |
| Cash, Cash Equivalents and Short-Term Investments | 321.83K | 136.49K | 344.63K | 680.17K | 2.05M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 29.75K | 39.81K | 85.33K | 154.65K | 927.71K |
| Stockholders Equity | 324.03K | 145.33K | 315.75K | 614.57K | 9.05M |
Cash Flow | |||||
| Free Cash Flow | -314.66K | -355.64K | -359.93K | -1.95M | -5.71M |
| Operating Cash Flow | -314.66K | -355.64K | -359.93K | -1.95M | -5.62M |
| Investing Cash Flow | 0.00 | 0.00 | 24.40K | 585.64K | -98.87K |
| Financing Cash Flow | 500.00K | 147.50K | 0.00 | 0.00 | 4.98M |
Entheon Biomedical Technical Analysis
Positive
0.10
Price Trends
0.10
Positive
0.10
Positive
0.10
Positive
Market Momentum
<0.01
Positive
55.03
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ENBI, the sentiment is Positive. The current price of 0.1 is below the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.10, and above the 200-day MA of 0.10, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 55.03 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:ENBI.
Entheon Biomedical Peers Comparison
UnderperformOutperform
Sector (51)
TSE:ENBI
Entheon Biomedical
0.10
-0.03
-23.08%
TSE:BETR
BetterLife Pharma
0.07
-0.02
-27.78%
TSE:HAVN
HAVN Life Sciences
0.03
0.00
0.00%
TSE:MYND
MYND Life Sciences
0.07
0.04
133.33%
TSE:IBO
Universal Ibogaine Inc
0.01
-0.01
-50.00%
TSE:MBIO
Mindbio Therapeutics Corp.
1.24
-2.76
-69.00%
Entheon Biomedical Corporate Events
Business Operations and StrategyM&A TransactionsPrivate Placements and FinancingStock Split
Entheon to Undergo Reverse Takeover by Nutravisor in Pivot to STRYK Brands
Positive
Jan 20, 2026
Entheon Biomedical has signed a definitive business combination agreement with Nutravisor Inc. under which Nutravisor will complete a reverse takeover of Entheon via a three-cornered amalgamation, resulting in Entheon acquiring all Nutravisor secu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.